Search

Oct 17, 2024
Milan based Enthera Pharmaceuticals is working in the autoimmune space with an asset that targets a unique pathway and that is the result of local research
CEO Lisa Olson describes the IGFBP3/TMEM219 axis and the antibody Enthera has designed to target it, all of which are the result of...